Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis

by Stéphane Paul, Hubert Marotte, Arthur Kavanaugh, Philippe Goupille, Tore K. Kvien, Marc deLongueville, Denis Mulleman, William J. Sandborn, Niels Vande Casteele
Published 2020-07-01

Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.

by Siddharth Singh, Antonio Facciorusso, Abha G Singh, Niels Vande Casteele, Amir Zarrinpar, Larry J Prokop, Eduardo L Grunvald, Jeffrey R Curtis, William J Sandborn
Published 2018-01-01

Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis

by Bryan Linggi, Vipul Jairath, Guangyong Zou, Lisa M. Shackelton, Dermot P. B. McGovern, Azucena Salas, Bram Verstockt, Mark S. Silverberg, Shadi Nayeri, Brian G. Feagan, Niels Vande Casteele
Published 2021-09-01

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease

by Ariela K. Holmer, Robert Battat, Parambir S. Dulai, Niels Vande Casteele, Nghia Nguyen, Anjali Jain, Ara Miralles, Jennifer Neill, Helen Le, Siddharth Singh, Jesus Rivera-Nieves, William J. Sandborn, Brigid S. Boland
Published 2020-11-01

Prospective randomised controlled trial of adults with perianal fistulising Crohn’s disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol

by Danny Liew, Ailsa Hart, Niels Vande Casteele, Jordi Rimola, Jane M Andrews, Jakob Begun, Yang Wu, Wei Xuan, Nik Sheng Ding, Bonita Gu, Michael De Gregorio, Joseph Louis Pipicella, William Connell, Basil D’Souza, Ali Gholamrezaei, Graham Radford-Smith, Tom Sutherland, Catherine Toong, Rodney Woods, Watson Ng
Published 2021-07-01